A global team of researchers has issued an urgent alarm: up to half of all chronic kidney disease cases worldwide go undiagnosed, leaving hundreds of millions of people vulnerable to a condition that kills faster than most realize. The revelation comes from a landmark series of papers published in The Lancet, led by Dr. Jennifer Lees from the University of Glasgow, and it paints a sobering picture of a global health crisis hidden in plain sight.
Chronic kidney disease currently affects 844 million adults worldwide and has already become the ninth leading cause of death globally—a ranking expected to worsen dramatically. By 2040, the disease is projected to rise to the fifth leading cause of death, surpassing conditions that now dominate public health conversations. In the UK alone, approximately 7.2 million people live with CKD, yet this staggering burden remains largely invisible because the disease develops silently. People with mild to moderate kidney disease rarely experience any symptoms, meaning the condition often progresses undetected until it reaches advanced stages, when dialysis or transplant becomes necessary.
The tragedy is that detection could be simple. A routine urine test—affordable and straightforward—can identify kidney disease early enough to change the course of treatment. Yet this test remains underutilized across health care systems worldwide. In high-income countries like the UK, an estimated 30 to 50 percent of CKD cases are never diagnosed by a doctor. In middle and lower-income countries, the percentage of undiagnosed cases is believed to be significantly higher, creating a global disparity that mirrors broader inequities in health care access.
The underdiagnosis problem is not distributed equally. Non-white populations and women are up to twice as likely as white men to remain undiagnosed—a gap that Dr. Lees emphasized demands urgent attention. Perhaps most striking: even among the one in ten people who do receive a CKD diagnosis, nine out of ten are unaware they actually have the condition, suggesting a failure not just in detection but in communication and follow-up care.
The economic implications are staggering. Kidney Research UK estimates that failing to address the diagnosis crisis in the UK alone could result in 650,000 additional people developing advanced chronic kidney disease by 2033, with annual costs to the economy nearly doubling to £13.9 billion. These are not abstract figures—they represent years of unnecessary suffering, premature deaths, and economic strain that could be prevented with earlier intervention.
Dr. Lees calls for a straightforward solution: routine urine testing across a wider range of health care settings, particularly for high-risk populations including those with heart disease, high blood pressure, or diabetes. The research series highlights not only the scale of underdiagnosis but also recent advances in treatment strategies that make early detection more actionable than ever before. The message is clear: the tools exist, and the evidence is overwhelming. What remains is the will to implement screening at scale and to prioritize those groups most likely to be overlooked by current systems.
This is a health crisis that remains largely unspoken, yet entirely addressable.